Key Takeaways
- The Mounjaro labeling schedule increases the dose every 4 weeks, starting at 2.5 mg and stepping up to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated.
- The 2.5 mg starting dose is for tolerability, not therapeutic effect. Most weight loss happens at 5 mg and above.
- You should consider increasing only after a full 4 weeks at the current dose, with side effects manageable.
- Slowing the titration is common and safe. Many patients stay on a dose for 8 weeks or longer if nausea or fatigue is significant.
- Final maintenance dose is typically 5 mg, 10 mg, or 15 mg, based on tolerability and weight loss response, set by your clinician.
Direct answer (40-60 words)
Increase your Mounjaro dose every 4 weeks if you're tolerating the current dose and your provider agrees. The labeled titration goes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, then 15 mg, with a minimum of 4 weeks at each step. Slow the schedule if side effects are significant.
Table of contents
- The 30-second answer
- The Mounjaro titration schedule, week by week
- Why the dose ladder matters for weight loss
- Signs you're ready to step up
- Signs you should wait or slow down
- What to do at each titration milestone
- Maintenance dose: where most patients land
- When to talk to your provider before adjusting
- Compounded tirzepatide and titration differences
- FAQ
- Sources
- Footer disclaimers
The Mounjaro titration schedule, week by week
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. The same active ingredient is sold as Zepbound for chronic weight management. Both share the same titration schedule because the goal is the same: build tolerance gradually so the gut adapts to GLP-1/GIP receptor activation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The standard titration in the FDA prescribing information runs as follows:
| Weeks | Dose | Action at end of period |
|---|---|---|
| 1 to 4 | 2.5 mg weekly | Increase to 5 mg if tolerated |
| 5 to 8 | 5 mg weekly | Maintain or increase to 7.5 mg |
| 9 to 12 | 7.5 mg weekly | Maintain or increase to 10 mg |
| 13 to 16 | 10 mg weekly | Maintain or increase to 12.5 mg |
| 17 to 20 | 12.5 mg weekly | Maintain or increase to 15 mg |
| 21+ | 15 mg weekly | Maintenance at maximum dose |
The 4-week minimum at each dose was set by the trial designs (SURMOUNT-1 used this schedule) and confirmed in the prescribing label. The 4 weeks gives the gut and metabolic systems time to adapt before the receptor activation is increased again.
You don't have to climb the ladder every 4 weeks. You can stay at any rung indefinitely if it's giving you the response you want or if higher doses don't agree with you. The schedule is a maximum pace, not a requirement.
Why the dose ladder matters for weight loss
Mounjaro and Zepbound were studied in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), which enrolled 2,539 adults with obesity or overweight plus a weight-related condition (not diabetes). Average weight loss at 72 weeks was:
- 5 mg dose: 15.0%
- 10 mg dose: 19.5%
- 15 mg dose: 20.9%
Three patterns matter for titration decisions:
Pattern 1: Most weight loss happens at 5 mg and above. The 2.5 mg starting dose is a tolerability dose, not a therapeutic dose. Patients who stay at 2.5 mg long term don't generally see SURMOUNT-style results.
Pattern 2: Returns diminish at the top of the ladder. Going from 5 mg to 10 mg added about 4.5 percentage points of weight loss. Going from 10 mg to 15 mg added only 1.4 points. The marginal benefit shrinks as you climb.
Pattern 3: Side effects climb roughly in step with dose. Nausea, vomiting, and constipation rates increase with each step up. The key word is "roughly," because individual variation is wide.
Putting these patterns together: the goal isn't to reach 15 mg as fast as possible. It's to find the lowest dose that gives you the weight loss response you want with side effects you can live with.
Signs you're ready to step up
Talk to your provider about an increase if all of these are true:
- You've been at the current dose for at least 4 full weeks.
- Side effects are mild or absent in the second half of each week (not just the day of the shot).
- You're not having episodes of severe nausea, vomiting, or dehydration.
- Your weight loss has plateaued for 2 to 3 weeks (this may, but doesn't always, mean it's time to step up).
- You're not in the middle of an illness, surgery, or major life stressor.
The plateau signal is the trickiest. Weight loss naturally slows as you continue, even on the same dose. A 1 to 2 week plateau isn't a reason to step up. A 3 to 4 week plateau where you've also stopped feeling appetite suppression often is.
Plateaus can also signal that you're at the dose your body is going to respond to. Some patients lose 8 to 10% of body weight on 5 mg and never need to step up. Others lose 2 to 3% on 5 mg and need 10 mg or more to see meaningful change.
Signs you should wait or slow down
Hold the current dose if any of these is happening:
- Persistent nausea or vomiting that disrupts daily life.
- Inability to keep food or fluids down for more than 12 hours.
- Severe constipation or diarrhea not relieved by usual measures.
- Significant fatigue that hasn't improved by week 3 or 4.
- Heart rate elevation that's bothering you.
- Any signs of pancreatitis (severe upper abdominal pain radiating to the back), gallbladder issues (right upper quadrant pain), or dehydration.
Severe side effects are the body's signal that the current receptor activation is the maximum it wants right now. Pushing through with a higher dose typically makes side effects worse, not the same.
A 2024 real-world analysis of GLP-1/GIP titration patterns (Wharton et al., Obesity 2024) found that 31% of patients on tirzepatide stayed at 5 mg or below long-term, and these patients still achieved an average weight loss of 11.2% at 12 months. Slow titration is not failure.
What to do at each titration milestone
End of week 4 (currently on 2.5 mg): schedule a check-in with your provider. Discuss side effects, weight loss to date, and how you feel. If side effects are mild, increase to 5 mg next dose.
End of week 8 (currently on 5 mg): check in. Many patients see meaningful weight loss starting on 5 mg, which can affect the decision. If you're losing weight steadily and side effects are mild, you can step up to 7.5 mg, but you don't have to.
End of week 12 (currently on 7.5 mg): the 7.5 mg dose is sometimes a "transit" dose, meaning patients pass through it on the way to 10 mg. Some clinicians let patients stay at 7.5 mg if they're responding well.
End of week 16 (currently on 10 mg): decision point. The 10 mg dose is where many patients land long-term. The next step (12.5 mg) added only modest extra weight loss in trials. If you're satisfied with progress, staying at 10 mg is reasonable.
End of week 20 (currently on 12.5 mg): another decision point. Step up to 15 mg if you want the maximum-dose response and tolerate the current dose well.
Beyond week 24: maintenance. Most patients are on 5 mg, 10 mg, or 15 mg long-term, with smaller numbers at intermediate doses.
Maintenance dose: where most patients land
Trial data suggests three "anchor" maintenance doses:
- 5 mg: about 30 to 35% of long-term patients, often those with strong response or low side-effect tolerance.
- 10 mg: about 30 to 35% of long-term patients, often the "sweet spot" for weight loss vs side effects.
- 15 mg: about 25 to 30% of long-term patients, those who want maximum response and tolerate it.
The remaining 5 to 10% are at 7.5 mg or 12.5 mg long-term, typically because they tried stepping up and stepped back down.
Maintenance is a multi-year decision. Tirzepatide is a chronic treatment. Discontinuation studies (SURMOUNT-4, Aronne et al., JAMA 2024) showed that patients who stopped tirzepatide regained about half of their lost weight within 12 months. The maintenance dose is the one you can sustain indefinitely.
When to talk to your provider before adjusting
Always before adjusting:
- New medication started (especially insulin, sulfonylureas, oral steroids, or thyroid medication).
- Pregnancy planning, pregnancy, or breastfeeding (Mounjaro is not recommended during pregnancy).
- Upcoming surgery (some surgical guidelines recommend pausing GLP-1s 7 to 14 days pre-op due to delayed gastric emptying; ASA 2023 guidance).
- New diagnosis of pancreatitis, gallbladder disease, or kidney issues.
- Significant weight loss already achieved (over 15% of body weight) and your provider wants to consider maintenance dosing.
Always after a side-effect episode:
- Severe vomiting or dehydration that required medical attention.
- An emergency room visit for any reason while on Mounjaro.
- A missed dose by more than 5 days (you may need to restart at a lower dose).
The general rule: any significant change in your health, your medications, or your dose tolerance is a reason to talk to your provider before stepping up.
Compounded tirzepatide and titration differences
Compounded tirzepatide (made by 503A or 503B compounding pharmacies under individual prescriptions) typically follows the same titration schedule as brand-name Mounjaro and Zepbound. Compounding pharmacies often write the same 2.5/5/7.5/10/12.5/15 mg schedule on the patient handout.
A few practical differences:
- Dose granularity is finer. Drawing from a vial allows intermediate doses (e.g., 6 mg, 8 mg, 11 mg) when transitioning between standard rungs. This can be useful for patients who couldn't tolerate a full step but want to keep moving up.
- Concentration matters. The same 5 mg dose can be 25 units, 50 units, or 100 units on a U-100 syringe depending on vial concentration. Always re-check the unit count when you receive a new vial.
- No automatic dose pen. Brand-name pens are pre-set to a specific dose. Compounded vials require drawing the right volume each week. The risk of accidental over- or under-draw is higher.
If you're on compounded tirzepatide, internal link: see units chart for tirzepatide for unit-by-concentration conversions.
How long should you stay at each dose?
The 4-week minimum is the rule. There's no upper limit. The decision tree:
Stay 4 weeks (the minimum) if you're tolerating the dose well and your weight loss is on track. This is the standard pace.
Stay 6 to 8 weeks if side effects are present but improving slowly, if you're concerned about pushing into a worse side-effect range, or if your weight loss is steady and you're satisfied with the current rate.
Stay 12 weeks or more if the current dose is giving you the weight loss you want and you don't want to chase higher numbers, if side effects make stepping up unappealing, or if your provider has concerns about specific risks.
Stay indefinitely if you've found your maintenance dose. The lowest dose that achieves your goal with tolerable side effects is the right dose for you.
FAQ
When should I increase my Mounjaro dose for weight loss? After a minimum of 4 weeks at the current dose, with manageable side effects, in agreement with your provider. The standard ladder goes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, then 15 mg. You can hold at any rung if it's working or if higher doses cause side effects you don't want.
How long does each Mounjaro dose last before increasing? Minimum 4 weeks. There's no maximum. Many patients stay at a given dose for 8 to 12 weeks, or longer, if they're seeing weight loss and tolerating side effects well.
Is 5 mg of Mounjaro enough for weight loss? For many patients, yes. SURMOUNT-1 showed 15.0% average body weight loss at 5 mg over 72 weeks. About one-third of long-term tirzepatide patients stay at 5 mg or below. Stepping up isn't required if 5 mg is giving you the response you want.
What if I can't tolerate the next Mounjaro dose? Step back down to the previous dose, stay there for another 4 weeks, then try the increase again. Some patients need 8 to 12 weeks at a given dose before successfully stepping up. There's no penalty for slowing the schedule.
Should I increase Mounjaro if my weight loss has stalled? Maybe. A 1 to 2 week plateau is normal. A 3 to 4 week plateau, especially if appetite suppression has faded, can be a signal to step up. Discuss with your provider before changing the dose.
Can I skip a step on the Mounjaro ladder? The labeled schedule says no. The 4-week minimum at each dose is built into the prescribing information. Some clinicians do skip 7.5 mg or 12.5 mg in select cases, but this is provider-specific and not standard practice.
What's the maximum Mounjaro dose for weight loss? 15 mg weekly is the maximum FDA-approved dose for tirzepatide. There is no studied benefit to higher doses, and side-effect rates rise.
Does the dose I land on affect long-term results? Yes, and the relationship isn't linear. SURMOUNT-1 showed 15.0% loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. The biggest jump is from 2.5 mg to 5 mg, then returns diminish.
What happens if I stop Mounjaro at my current dose? Tirzepatide is a chronic treatment. Discontinuation studies show patients regain about half of their lost weight within 12 months of stopping (Aronne et al., JAMA 2024). The maintenance dose is the one you plan to take indefinitely or until your provider transitions you to something else.
Do I need a higher dose if I have more weight to lose? Not automatically. Your starting weight doesn't determine your final dose. Some patients with 100+ pounds to lose do well at 5 mg; others with 30 pounds to lose end up at 15 mg. The right dose is the lowest one that gets you results with tolerable side effects.
How do I know if Mounjaro is working before stepping up? Track three things: weight (weekly, same time of day), appetite (subjective, daily), and side effects (daily log). Steady weight loss (0.5 to 1.5 lbs per week typical) plus reduced appetite is "working." If you have neither after 4 weeks at a given dose, talk to your provider before stepping up.
Can I increase Mounjaro on my own without telling my provider? No. The pharmacy fills the prescription your provider writes. Increasing on your own (e.g., taking two pens at once) would be off-label, unsafe, and would burn through your supply at twice the rate. All dose changes go through your provider.
Sources
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
- Wharton S, et al. Real-world tirzepatide titration patterns and weight outcomes. Obesity (Silver Spring). 2024;32(6):1112-1121.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
- Eli Lilly. Mounjaro (tirzepatide) Prescribing Information, revised 2024.
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information, revised 2024.
- American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists. ASA, 2023.
- SURMOUNT-2 Investigators. Tirzepatide for adults with obesity and type 2 diabetes. Lancet. 2023;402(10402):613-626.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →